Skip to main content

Table 4 Primary outcome results

From: Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?

  ELIXA [22] LEADER [24] SUSTAIN-6 [25] EXSCEL [27, 28] Harmony outcomes [30] PIONEER 6 [32] REWIND [34]
  Lixisenatide Placebo Liraglutide Placebo Semaglutide Placebo Exenatide Placebo Albiglutide Placebo Semaglutide Placebo Dulaglutide Placebo
N 3034 3034 4668 4672 1648 1649 7356 7396 4731 4732 1591 1592 4949 4952
MACE (per 100 patient-yr) 6.40 6.30 3.40* 3.90 3.24* 4.44 3.70 4.00 4.57* 5.87 2.90* 3.70 2.35* 2.66
CV death 2.30 2.40 1.20* 1.60 1.29 1.35 1.40 1.50 1.61 1.72 0.70 1.40 1.22 1.34
Non-fatal MI 4.20 4.10 1.60 1.80 1.40 1.92 (2.10)
(fatal or nonfatal)
(2.10)
(fatal or nonfatal)
(2.43) *
(fatal or nonfatal)
(3.26)
(fatal or nonfatal)
1.80 1.50 0.80 0.84
Non-fatal stroke 1.00 0.90 0.90 1.00 0.80* 1.31 (0.80)
(fatal or nonfatal)
(0.90)
(fatal or nonfatal)
(1.25)
(fatal or nonfatal)
(1.45)
(fatal or nonfatal)
0.60 0.80 0.52* 0.69
UA 0.20 0.10 (0.7) (0.7) (0.65) (0.80) N/A N/A N/A N/A (0.50) (0.30) (0.34) (0.30)
  1. CV cardiovascular, MACE major adverse cardiovascular outcome, MI myocardial infarction, N/A not applicable, UA unstable angina
  2. *Statistically significant difference